RecruitingPhase 2NCT07372040

Add-on Diuretics in Acute Decompensated Heart Failure

Clinical Study Comparing Empagliflozin, Acetazolamide, and Metolazone as Add-on Therapies to Loop Diuretics in Acute Decompensated Heart Failure


Sponsor

Tanta University

Enrollment

66 participants

Start Date

Feb 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study is to compare the efficacy and safety of empagliflozin, acetazolamide, and metolazone as add-on therapies to loop diuretics in patients with acute decompensated heart failure.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether adding extra diuretic medications (water pills) to standard treatment can help people hospitalized with a flare-up of heart failure (called acute decompensated heart failure) shed excess fluid more effectively and recover faster. **You may be eligible if...** - You are over 18 years old - You have been admitted to hospital with a diagnosis of acute decompensated heart failure - You have visible signs of fluid buildup such as leg swelling, abdominal fluid, or fluid around the lungs **You may NOT be eligible if...** - You have type 1 diabetes - Your kidneys are very poorly functioning (eGFR below 30) or you are on dialysis - Your blood pressure is very low (systolic below 90 mmHg) - You are in cardiogenic shock (severely low heart output) - You received certain diuretics (SGLT2 inhibitors, thiazides) in the 48 hours before joining the study - You have moderate to severe anemia - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGempagliflozin

Empagliflozin may augment the natriuretic and aquaretic actions of loop diuretics in patients with acute decompensated heart failure and it does not typically cause electrolyte disturbances and has been shown to improve outcomes in patients with heart failure

DRUGAcetazolamide

Acetazolamide can augment the action of loop diuretics in patients with acute decompensated heart failure

DRUGmetolazone

Metolazone can augment the action of loop diuretics in patients with acute decompensated heart failure


Locations(1)

Tanta university

Tanta, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07372040


Related Trials